Johnson & Johnson [NYSE: JNJ] COVID-19 Vaccine Gets FDA Panel Recommendation

Johnson & Johnson [NYSE: JNJ] revealed that its COVID-19 vaccine candidate has got a green signal from the panel of the FDA. The firm disclosed that US FDA VRBPAC has supported the EUA for the single-shot COVID-19 vaccine candidate of JNJ. The vaccine candidate of the firm is for adults 18 and older, created by the Janssen Pharmaceutical Companies of JNJ.

The recommendation of the FDA panel solely based on the protection and effectiveness data related to the vaccine candidate of the firm. The firm has shared the safety report from the Phase 3 ENSEMBLE research. After the reference, the next move of the FDA which the firm is waiting for is to get a EUA for its vaccine candidate.

Share of Johnson & Johnson [NYSE: JNJ] plunged 2.64% after the firm lost -4.30 during the trading session of Friday. JNJ has recorded the trading volume of 14.06 million as compared to the average volume of 8.12 million. JNJ’s share surged 45.16% from its 52-weeks low and plunged -8.75% from its 52-week high. JNJ market capitalization has reached $424.22 billion at the time of writing.

JNJ is planning to provide its vaccine candidate non-profit basis to stop the spread of novel coronavirus. JNJ is intending to supply its vaccine shot as soon as possible after getting the EUA. JNJ disclosed that if the firm received EUA it will supply enough doses through the completion of March to allow the full inoculation of more than 20 million people in the U.S. The firm intends to supply 100 million single-dose vaccines to the U.S. during the first half of 2021.

Not long ago, JNJ also declared its filing of a European Conditional MA Application to the EUL with the WHO for its COVID-19 vaccine candidate. JNJ COVID-19 single-dose vaccine candidate is compliant with the typical vaccine preservation and dissemination channels with the convenience of shipment to faraway areas.